DPP1 Anti-inflammatory Window Opens: QCS Custom-Synthesises Hard-to-Source Brensocatib Impurities

Tempo：2026-09-02

01 Product Overview: the First DPP1 Inhibitor, Ending a 50-Year Wait for a Targeted Therapy

Molecular formula	C₂₃H₂₄N₄O₄
Molecular weight	420.47 g/mol
CAS	1802148-05-5 (free base); 2923839-30-7 (hydrate)
Chemical name	(S)-N-((S)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide

A “source-level anti-inflammatory” arrives in a vast respiratory market

Bronchiectasis is a chronic, progressive and irreversible destruction of the airways: patients are trapped in a cycle of recurrent infection and inflammation while lung function declines year after year. Non-cystic fibrosis bronchiectasis (NCFB) affects a very large population worldwide, yet before brensocatib there was no approved therapy that targeted the disease itself — care was limited to symptom management.

On 12 August 2025 the US FDA approved brensocatib (BRINSUPRI), developed by Insmed Incorporated — the first dipeptidyl peptidase 1 (DPP1) inhibitor ever approved, indicated for non-cystic fibrosis bronchiectasis. On 24 August 2026 Japan’s Ministry of Health, Labour and Welfare followed with its own approval.

Highlights

• Novel mechanism: the first reversible DPP1 inhibitor — neither immunosuppressive nor antibiotic

• Source-level control: acts at the neutrophil maturation stage in the bone marrow, modulating inflammation without weakening immunity

• Hard-endpoint benefit: the Phase III ASPEN study showed a significant reduction in the annual rate of pulmonary exacerbations and slower decline in lung function

• Market potential: widely seen as the next potential blockbuster in respiratory medicine

02 Patents and Timing: NCE Exclusivity Runs to 2030 — the Research Window Is Already Open

Analysis: as a new molecular entity, brensocatib enjoys five years of regulatory exclusivity — the FDA will not accept generic applications before August 2030. But impurity work is not a last-minute sprint; it is a systematic programme that must start two to three years ahead. Chiral method development, mapping of cyano degradation impurities and genotoxic risk assessment each take six to twelve months. Starting now means completing the full impurity package before exclusivity expires.

03 Impurity Profile: Four Directions, None of Which Can Be Skipped

Brensocatib carries one chiral centre, one cyano group, one amide bond, one benzoxazolone ring and one seven-membered oxazepane ring — a dense set of functional groups, a complex synthetic route and a consequently broad impurity profile.

▪ 01 Chiral impurities: gatekeepers of a single configuration

▪ 02 Process-related impurities: starting materials, by-products and intermediates

▪ 03 Degradation impurities: the cyano group and the amide bond are the weak points

▪ 04 Potential genotoxic impurities

04 Our Custom Synthesis Capability

We have analysed the molecular structure and synthetic route of brensocatib in depth and built a complete impurity synthesis plan around the core needs of generic-drug impurity studies.

Process development support

✅ Evaluation and optimisation of stereoselective synthetic routes

✅ Screening of key step conditions (amidation, crystallisation, polymorph control)

✅ Analytical method development support (chiral methods, impurity identification)

Delivery standards

✅ Purity ≥95% (higher purity available on request)

✅ Full CoA, MS, NMR and HPLC data supplied with every lot

✅ Strict confidentiality; NDAs available

Why work with us

✓ Expert team — PhD and MSc scientists with years of pharmaceutical and CRO experience

✓ In-house instrumentation — our own NMR, MS and preparative HPLC, no outsourcing

✓ Competitive pricing — below comparable products on the market

✓ Proven track record — impurity reference standards supplied to numerous generic-drug manufacturers

05 Act Now

Brensocatib was approved in August 2025 and holds NCE exclusivity until August 2030. That leaves a four-year research window — and chiral method development, cyano degradation impurity mapping and genotoxic risk assessment each require six to twelve months.

Starting now puts you exactly on schedule. Synthesis of the relevant impurities is already under way — talk to us.

View the full brensocatib standard range →

ANAB ISO 17034 QCS holds ANAB ISO 17034 accreditation. Our reference standard production and value assignment processes meet the international requirements for competence of reference material producers, providing data with international mutual recognition for NMPA, EMA and FDA submissions.